Prime Medicine received clearance from New Zealand’s Medsafe to proceed with its clinical trial application for PM-577a, an investigational Prime Editor targeting Wilson’s disease. The company said the regulatory step authorizes initiation in New Zealand, supporting further clinical evaluation of the gene-editing approach. Wilson’s disease involves impaired copper handling driven by genetic defects, making it a high-value target for potentially curative genome-editing strategies. Prime Medicine’s entry point reflects the broader shift from preclinical prime editing toward region-by-region clinical execution. The clearance positions PM-577a for continued advancement as the company prepares for ongoing enrollment and follow-on regulatory steps in additional jurisdictions, depending on trial design requirements.